IO BIOTECH
IO Biotech is a clinical stage biotech company developing disruptive immune therapies for the treatment of cancer. The pipeline of first-in-class immune modulating anti-cancer therapies is developed by a unique technology platform, T-win®, enabling the activation of T cells that are specific for immune-suppressive molecules. IO Biotech has a proven track record of progressing preclinical and clinical compounds. The two lead compounds targeting IDO and PD-L1 are in clinical development and several pipeline compounds are in pre-clinical phase.
IO BIOTECH
Industry:
Biotechnology Health Care Therapeutics
Founded:
2014-12-23
Address:
Copenhagen, Hovedstaden, Denmark
Country:
Denmark
Website Url:
http://www.iobiotech.com
Total Employee:
11+
Status:
Active
Contact:
(452)194-7856
Email Addresses:
[email protected]
Total Funding:
175.01 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Mobile Non Scaleable Content Nginx
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
ALX Oncology
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
amcure
amcure is a clinical-stage company develops peptide-based compounds for the treatment of highly metastatic forms of squamous cancer.
aratinga.bio
aratinga.bio is a preclinical-stage biotech company developing novel immunotherapies to treat cancer.
Bright Peak Therapeutics
Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases.
EiRx Therapeutics
EiRx Therapeutics operates as a research-driven healthcare company developing targeted therapies for the treatment of cancer.
GamaMabs Pharma
GamaMabs Pharma is a clinical-stage immuno-oncology company that developes optimized therapeutic antibodies for the treatment of cancer.
Gritstone Bio
Gritstone Oncology is a clinical-stage biotech company that develops tumor-specific cancer immunotherapies to fight multiple cancer types.
Harpoon Therapeutics
Harpoon Therapeutics is a clinical-stage immunotherapy company developing novel T cell engagers (TriTACs) for the treatment of cancer.
Hookipa Pharma
Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.
Innoskel
InnoSkel is a pioneering platform biotechnology company developing therapies for rare skeletal diseases.
Milestone Pharmaceuticals
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
NorthSea Therapeutics
NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics.
SNIPR Biome
SNIPR Biome is a operator of a discovery stage biotech company intended to revolutionize the treatment of microbial diseases.
X4 Pharmaceuticals
X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment.
Xeltis
Xeltis is a clinical-stage medtech company with the world’s most advanced polymer-based platform of restorative cardiovascular devices.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series C - IO Biotech
Serrado Capital
Serrado Capital investment in Series B - IO Biotech
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series B - IO Biotech
Lundbeckfonden Emerge
Lundbeckfonden Emerge investment in Series B - IO Biotech
Sunstone Life Science Ventures
Sunstone Life Science Ventures investment in Series B - IO Biotech
Idinvest Partners
Idinvest Partners investment in Series B - IO Biotech
Vivo Capital
Vivo Capital investment in Series B - IO Biotech
Novo Holdings
Novo Holdings investment in Series B - IO Biotech
Kurma Partners
Kurma Partners investment in Series B - IO Biotech
EIR Ventures
EIR Ventures investment in Series B - IO Biotech
Official Site Inspections
http://www.iobiotech.com Semrush global rank: 9.5 M Semrush visits lastest month: 145
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "IO Biotech"
IO Biotech - Crunchbase Company Profile & Funding
IO Biotech is a clinical stage biotech company developing disruptive immune therapies for the treatment of cancer. The pipeline of first-in-class immune modulating anti-cancer therapies is developed by a unique technology …See details»
IO Biotech, Inc. (IOBT) Company Profile & Facts - Yahoo Finance
See the company profile for IO Biotech, Inc. (IOBT) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives …See details»
IO Biotech, Inc. - Governance - Board of Directors
During his career, he was o.a. President of the the EORTC (European Organization for Research and Treatment of Cancer) from 2003 to 2006 and President of ECCO (European CanCer Organization) from 2008 to 2010, and …See details»
IO Biotech, Inc. - Invest in combination cancer therapy
Nov 11, 2024 IO Biotech is a clinical-stage biopharmaceutical company pioneering the first dual-action immune-modulating cancer vaccine with the goal of becoming the backbone of …See details»
IO Biotech, Inc. - Governance - Executive Management
Dr. Zocca also led DanDrit Biotech A/S, a biotechnology company, as its Chief Executive Officer from July 2007 until December 2010. Dr. Zocca currently serves on the board of directors for Dansk Biotek, a Danish biotechnology …See details»
IO Biotech - LinkedIn
IO Biotech is a clinical-stage biopharmaceutical company pioneering the first-in-class investigational dual-action immune-modulating cancer vaccine with the goal of becoming the …See details»
IO Biotech, Inc. (IOBT) Company Profile & Overview - Stock Analysis
Nov 5, 2021 Ticker Symbol: IOBT: Exchange: NASDAQ: Fiscal Year: January - December: Reporting Currency: USD: IPO Price: $14.00: CIK Code: 0001865494: CUSIP Number: …See details»
IO Biotech - HBM Healthcare
Www.iobiotech.com. Company status: Public. Description - IO Biotech is a clinical stage biotech company developing disruptive immune therapies for the treatment of cancer. Our pipeline of …See details»
IO Biotech - Craft
Oct 2, 2024 IO Biotech is a clinical-stage biotech company developing immune-modulating cancer therapies. It utilizes the T-win technology platform and develops IO102-IO103 designed …See details»
Science - IO Biotech
Nov 7, 2024 During his career, he chaired the EORTC (European Organization for Research and Treatment of Cancer) from 2003 to 2006 and ECCO (European CanCer Organization) from …See details»
IO Biotech, Inc. (IOBT) - Yahoo Finance
Find the latest IO Biotech, Inc. (IOBT) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
IO Biotech Completes Enrollment in Phase 2 Trial of its
5 hours ago [email protected]. Media Julie Funesti Salutem 917-498-1967 [email protected] ...See details»
IO Biotech, Inc. - News & Events - News
Oct 4, 2024 We announce the most recent appointments, events, conferences and presentations at IO Biotech.See details»
IO Biotech Completes Enrollment in Phase 2 Trial of its …
5 hours ago -- Enrollment Completed Ahead of Schedule -- -- Initial Data Expected in 2025 -- NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical …See details»
IO Biotech Completes Enrollment in Phase 2 Trial of its …
5 hours ago For further information, please visit www.iobiotech.com. Follow us on our social media channels on LinkedIn and X (@IOBiotech). Forward-Looking Statement This press …See details»
IO Biotech Announces Appointment of New Chief Financial Officer
NEW YORK, Oct. 13, 2022 (GLOBE NEWSWIRE) - IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on …See details»
Careers - IO Biotech
During his career, he chaired the EORTC (European Organization for Research and Treatment of Cancer) from 2003 to 2006 and ECCO (European CanCer Organization) from 2008 to 2010. …See details»
IO Biotech Completes Enrollment in Phase 2 Trial of its …
5 hours ago [email protected]. Media Julie Funesti Salutem 917-498-1967 [email protected] Markets Insider and Business Insider Editorial Teams were …See details»
IO Biotech Completes Enrollment in Phase 2 Trial of its ... - BioSpace
2 hours ago For further information, please visit www.iobiotech.com. Follow us on our social media channels on LinkedIn and X . Forward-Looking Statement. This press release contains …See details»
IO Biotech Announces Positive Results from Phase 2 Trial of IO102 …
NEW YORK, Sept. 14, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic …See details»